rFIXFc is a fully-recombinant clotting factor developed using Biogen Idec’s proprietary monomeric Fc-fusion technology. In the B-Long trial, rFIXFc’s ability to prevent bleeding using different dosing regimens will be measured by evaluating the number of breakthrough bleeding episodes annualized over the study period.
The study will also evaluate the efficacy of rFIXFc in on-demand and surgical settings, and compare the pharmacokinetics of a single dose of rFIXFc with a single dose of a commercially available recombinant Factor IX product.
Glenn Pierce, vice president and chief medical officer of hemophilia therapeutic area at Biogen Idec, said: “We are excited that rFIXFc is the first long-acting Factor IX therapy to enter registrational trials. We are making important progress in our efforts to develop a treatment that can make a difference to the hemophilia B community.”
Peter Edman, chief scientific officer of Swedish Orphan Biovitrum, said: “rFIXFc is an innovative therapy that offers the potential to make a positive impact in the lives of people with hemophilia B. Enrolling a patient in our first registrational trial is also a notable achievement for Swedish Orphan Biovitrum.”
Using the same proprietary technology as rFIXFc, Biogen Idec and Swedish Orphan Biovitrum are also developing a fully-recombinant, long-acting Factor VIII Fc fusion protein (rFVIIIFc), for the treatment of hemophilia A. rFVIIIFc is currently being evaluated in a phase I/IIa, open-label, dose-escalation, multicenter study to evaluate the safety, tolerability and pharmacokinetics of rFVIIIFc in hemophilia A patients.